मूलभूत आँकड़े
| CIK | 1706431 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vir Biotechnology, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| August 6, 2025 |
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results – ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical pipeline with three ongoing Phase 1 studies – Strong financial position and runway |
|
| July 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 24, 2025 |
Exhibit 99.1 Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors –Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such as NSCLC, CRC |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2025 |
Exhibit 99.1 Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study –HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively –As previously announced, Phase 3 development i |
|
| May 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and among VIR BIOTECHNOLOGY, INC. and ALNYLAM PHARMACEUTICALS, INC. dated as of March 7, 2025 Execution Version AMENDED AND REST |
|
| May 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| May 7, 2025 |
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results – Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations – Dose escalation continues for PRO-XTEN™ dual-masked T-cell engag |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Def |
|
| April 17, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 26, 2025 As filed with the Securities and Exchange Commission on February 26, 2025 Registration No. |
|
| February 27, 2025 |
Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan Exhibit 10.15 VIR BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN APPROVED BY THE BOARD OF DIRECTORS: MARCH 11, 2019, and Amended and Restated effective as of January 1, 2025 Section 1. INTRODUCTION. The Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan (the “Plan”) established March 11, 2019 (the “Effective Date”) is hereby amended and restated effective as of |
|
| February 27, 2025 |
Exhibit 19 Insider Trading Policy 1.0INTRODUCTION During the course of your relationship with Vir Biotechnology, Inc. (the “Company”), you may receive material information that is not yet public (“material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships. Material nonpublic information may give you, or someone you |
|
| February 27, 2025 |
List of subsidiaries of the Company Exhibit 21.1 Subsidiaries of Vir Biotechnology, Inc. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Agenovir Corporation Delaware Encentrio Therapeutics, Inc. Delaware Humabs BioMed SA Switzerland TomegaVax, Inc. Delaware Vir AU Biotechnology Pty Ltd. Australia |
|
| February 27, 2025 |
Vir Biotechnology, Inc. Discretionary Bonus Plan Exhibit 10.9 VIR BIOTECHNOLOGY, INC. DISCRETIONARY BONUS PLAN ARTICLE 1 PURPOSE OF THE PLAN This Discretionary Bonus Plan (the “Plan”) is established to provide an incentive to selected employees to promote the success of Vir Biotechnology, Inc. (the “Company”) by offering an opportunity to receive additional compensation based on corporate performance measured against corporate goals, adjusted fo |
|
| February 27, 2025 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vir Biotechnology, Inc. |
|
| February 27, 2025 |
Letter between the Company and M EX-10.13 5 a20241231-ex1013offerlette.htm EX-10.13 OFFER LETTER (MARK EISNER) Exhibit 10.13 May 20, 2024 [***] [***] [***] Dear Mark, Congratulations! We are excited to welcome you to Vir Biotechnology, Inc. (“Vir” or the “Company”). It is my pleasure to extend an offer as a full-time employee of Vir. Title and Reporting Relationship: You will have the position of Executive Vice President, Chief M |
|
| February 27, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.8 VIR BIOTECHNOLOGY, INC. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Polic |
|
| February 27, 2025 |
Promotion Letter between the Company and Vanina de Verneuil, dated November 1, 2023 Exhibit 10.12 November 1, 2023 Dear Vanina, I want to thank you for your contributions to Vir, and to let you know that they are very much appreciated. I am pleased to announce your promotion to EVP, General Counsel and Corporate Secretary. As a result of your promotion, you will receive a base salary increase of $45,000, bringing your new base salary to $470,000 effective November 1, 2023. This i |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 |
|
| February 26, 2025 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results – Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 – Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations – |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 18, 2025 |
POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Vir Biotechnology, Inc. |
|
| February 13, 2025 |
POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Vir Biotechnology, Inc. |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 8, 2025 |
EX-99.1 Exhibit 99.1 Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC • Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors • VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage obser |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 4, 2024 |
Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT between AMUNIX PHARMACEUTICALS, INC. and VIR BIOTECHNOLOGY, INC. Dated as of July 31, 2024 TABLE OF CONTENTS Page ARTICLE 2 GRANT OF RI |
|
| November 4, 2024 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Other Transaction Agreement No. 75A50122C00081 Amendment No. P00003 OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR) Agreement No.: 75A50122C00081 BETWEEN VIR BIOTECHNOLOGY, INC. (“Recipient |
|
| November 4, 2024 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Other Transaction Agreement No. 75A50122C00081 Amendment No. P00002 OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR) Agreement No.: 75A50122C00081 BETWEEN VIR BIOTECHNOLOGY, INC 1800 OWENS S |
|
| November 4, 2024 |
Offer Letter between the Company and J Exhibit 10.2 September 6, 2024 [***] [***] [***] Dear Jason, Congratulations! We are excited to welcome you to Vir Biotechnology, Inc. (“Vir” or the “Company”). It is my pleasure to extend an offer to you as a full-time employee on behalf of Vir. Title, Working Location, and Reporting Relationship: You will have the position of Executive Vice President, Chief Financial Officer, working in Vir’s of |
|
| November 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 31, 2024 |
Exhibit 99.1 Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 2025 – – Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024 – – |
|
| October 18, 2024 |
VIR / Vir Biotechnology, Inc. / STATE STREET CORP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIR BIOTECHNOLOGY INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92764N102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| September 10, 2024 |
Exhibit 99.2 Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer – Seasoned biotech executive brings decades of effective financial leadership to Vir – SAN FRANCISCO, September 10, 2024 – Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne wil |
|
| September 10, 2024 |
Exhibit 99.1 Vir Biotechnology announces closing of exclusive worldwide license agreement with Sanofi for multiple potential best-in-class clinical-stage T-Cell engagers – License of proprietary masking platform further strengthens Vir’s drug discovery capabilities in oncology and infectious disease – – Strategic agreement expands Vir portfolio with three clinical stage assets in areas of high unm |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2024 |
Exhibit 99.1 Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities – Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy – – Exclusive license agreem |
|
| August 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| June 26, 2024 |
Exhibit 99.1 Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta SAN |
|
| June 5, 2024 |
EX-99.1 Exhibit 99.1 Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment – Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call schedu |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 3, 2024 |
Letter Agreement between the Company and Glaxo Wellcome UK Limited, dated February 21, 2024. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. February 21, 2024 Glaxo Wellcome UK Limited 980 Great West Road, Brentford, Middlesex, TW8 9GS Attn: SVP & Head R&D Business Development Re: Termination of Influenza Progr |
|
| May 3, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| May 2, 2024 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results – Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 billion in cash, cash equivalents and investments |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 19, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 18, 2024 |
Exhibit 99.1 Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors SAN FRANCISCO, April 18, 2024 – Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on |
|
| February 26, 2024 |
As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration No. |
|
| February 26, 2024 |
Dodd-Frank Compensation Recovery Policy Exhibit 97 VIR BIOTECHNOLOGY, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Vir Biotechnology, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank W |
|
| February 26, 2024 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vir Biotechnology, Inc. |
|
| February 26, 2024 |
List of subsidiaries of the Company. Exhibit 21.1 Subsidiaries of Vir Biotechnology, Inc. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Agenovir Corporation Delaware Encentrio Therapeutics, Inc. Delaware Encentrio Therapeutics International GmbH Switzerland Humabs BioMed SA Switzerland TomegaVax, Inc. Delaware Vir AU Biotechnology Pty Ltd. Australia Vir Biotechnology International GmbH Switzerland Vi |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 |
|
| February 22, 2024 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results – Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to complete e |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2024 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| February 13, 2024 |
VIR / Vir Biotechnology, Inc. / SB INVESTMENT ADVISERS (UK) LTD Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N102 (CUS |
|
| February 13, 2024 |
VIR / Vir Biotechnology, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02224-virbiotechnologyinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Vir Biotechnology Inc Title of Class of Securities: Common Stock CUSIP Number: 92764N102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to de |
|
| December 13, 2023 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR) Agreement No.: 75A50122C00081 BETWEEN VIR BIOTECHNOLOGY, INC 1800 OWENS STREET, SUITE 900 SAN FRANCISCO, CA 94158 AND THE UNITED STATES OF AM |
|
| November 3, 2023 |
Exhibit 1.2 VIR BIOTECHNOLOGY, INC. $300,000,000 COMMON STOCK SALES AGREEMENT November 3, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Vir Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from |
|
| November 3, 2023 |
Exhibit 4.7 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| November 3, 2023 |
Exhibit 4.5 VIR BIOTECHNOLOGY, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapp |
|
| November 3, 2023 |
ness and Response, Biomedical Advanced Research and Development Authority Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR) BETWEEN Vir Biotechnology, Inc. 499 Illinois St, Suite 500 San Francisco, CA 94158 AND THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND |
|
| November 3, 2023 |
Exhibit 10.1 Separation Agreement by and between Vir Biotechnology International GmbH Grafenauweg 8, 6300 Zug (hereinafter the Company) and Johanna Friedl-Naderer [Address] (hereinafter the Employee) (each a Party, together the Parties) Separation Agreement by and between Vir Biotechnology International GmbH and Johanna Friedl-Naderer Whereas A.Humabs BioMed SA, Bellinzona and the Employee entered |
|
| November 3, 2023 |
Exhibit 4.8 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| November 3, 2023 |
Form of Subordinated Indenture. Exhibit 4.6 VIR BIOTECHNOLOGY, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vir Biotechnology, Inc. |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| November 2, 2023 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results – Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials – – Company expanding strategic focus to autoimmune diseases and immuno-oncology – – Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, ef |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 3, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2023 |
Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results – Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform – – First participant to be dosed in Phase 1 trial of ne |
|
| July 20, 2023 |
EX-99.1 Exhibit 99.1 Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness SAN FRANCISCO, JULY 20, 2023 – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2023 |
Offer Letter between the Company and Sung Lee, dated February 13, 2023 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. February 13, 2023 Sung Lee [***] [***] Dear Sung, Congratulations! We are excited to welcome you to Vir Biotechnology, Inc. (“Vir” or the “Company”). It is my pleasure to extend an offer a |
|
| May 8, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Execution Version AMENDMENT NO. 2 TO DCA This Amendment No. 2 (this “Second Amendment”) to that certain Definitive Collaboration Agreement dated as of June 9, 2020, as amended on May 27, 2 |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| May 8, 2023 |
Offer Letter between the Company and Marianne De Backer, dated January 19, 2023 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. VIA ELECTRONIC MAIL January 19, 2023 Marianne De Backer Dear Marianne, On behalf of Vir Biotechnology, Inc. (“VirBio” or the “Company”), I am pleased to offer you employment with the Compa |
|
| May 8, 2023 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Execution Version AMENDMENT NO. 3 TO DCA This Amendment No. 3 (this “Third Amendment”) to that certain Definitive Collaboration Agreement dated as of June 9, 2020, as amended on May 27, 20 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2023 |
Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results – Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth – – $2.3 billion in cash, cash equivalents, and investments as o |
|
| April 7, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| March 8, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VIR BIOTECHNOLOGY, INC. (A DELAWARE CORPORATION) March 2, 2023 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 6 Sec |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology |
|
| February 28, 2023 |
List of subsidiaries of the Company. Exhibit 21.1 Subsidiaries of Vir Biotechnology, Inc. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Agenovir Corporation Encentrio Therapeutics, Inc. Encentrio Therapeutics International GmbH Humabs BioMed SA Statera Health, LLC TomegaVax, Inc. Vir AU Biotechnology Pty Ltd. Vir Biotechnology International GmbH Vir Predictive Medicine, Inc. VirAb, Inc. Delaware Dela |
|
| February 28, 2023 |
(incorporated herein by reference to Exhibit 10. Exhibit 10.8 VIR BIOTECHNOLOGY, INC. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Polic |
|
| February 28, 2023 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vir Biotechnology, Inc. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Exhibit 10.17 AGREEMENT ON TRANSFER OF EMPLOYMENT AND AMENDMENT OF EMPLOYMENT AGREEMENT ("Agreement") Dated: December 19, 2022 Between Humabs BioMed SA (“Humabs”) Via dei Gaggini 3 6500 Bellinzona, Switzerland A subsidiary of Vir Biotechnology, Inc. (“VIR”) 499 Illinois Street, Suite 500 San Francisco, CA 94158 USA And Vir Biotechnology International GmbH (“VBI”) Grafenauweg 8 6300 Zug, Switzerlan |
|
| February 23, 2023 |
Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results – Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 – – Strong balance sheet expecte |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2023 |
EX-99 2 d436865dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| February 14, 2023 |
VIR / Vir Biotechnology Inc / SOFTBANK VISION FUND (AIV M1) L.P. - SC 13G/A Passive Investment SC 13G/A 1 d436865dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of S |
|
| February 13, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| February 9, 2023 |
VIR / Vir Biotechnology Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02195-virbiotechnologyinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Vir Biotechnology Inc. Title of Class of Securities: Common Stock CUSIP Number: 92764N102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to d |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2022 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir B |
|
| November 3, 2022 |
Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results ? Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million with potential total of up to $1.0 billion ? ? Phase 2 data from three of the Company?s most adva |
|
| October 4, 2022 |
Exhibit 99.1 Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats ? First award from the agency?s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza ? ? Initial investment of approximately $55 million from Biomedical Advanced Research and Development Authority to support development of VIR-2482, an |
|
| October 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commiss |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone N |
|
| August 9, 2022 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotec |
|
| August 9, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. |
|
| August 9, 2022 |
Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results ? More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company?s ongoing operations and liabilities for up to five years ? ? Company provides update on COVID-19 development program and outlines multiple anticipate |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone N |
|
| May 5, 2022 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biote |
|
| May 5, 2022 |
EX-99.1 2 vir-ex991.htm EX-99.1 Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results - $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter - - More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – - Encouraging initial data from MARCH trial evalu |
|
| May 5, 2022 |
1 Exhibit 10.1 EMPLOYMENT AGREEMENT (hereinafter the "Agreement") between Humabs BioMed SA Via dei Gaggini 3 6500 Bellinzona Switzerland (hereinafter the "Employer") and Johanna Friedl-Naderer (hereinafter the "Employee") (the Employer and the Employee together the "Parties", each a "Party") 1. Preamble A. Whereas, the Employer, with registered seat in Bellinzona and registered under the company n |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 7, 2022 |
DEF 14A 1 d270909ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| April 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission F |
|
| March 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| March 25, 2022 |
Exhibit 99.1 US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant SAN FRANCISCO, March 25, 2022 ? GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology |
|
| February 28, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vir Biotechnology, Inc. |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 10.45 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. January 12, 2022 Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco, CA 94158 Re: Strategic Relationship between the Bill & Melinda Gates Foundation and |
|
| February 28, 2022 |
Exhibit 10.47 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. GRANT AGREEMENT Investment ID INV-033423 AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Vir Biotechnology Inc Tax Status: Not exempt from federal income tax |
|
| February 28, 2022 |
EXHIBIT 10.66 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. LEASE THE EXCHANGE KRE EXCHANGE OWNER LLC a Delaware limited liability company as Landlord, and VIR BIOTECHNOLOGY, INC., a Delaware corporation As Tenant. 1800 Owens Stre |
|
| February 28, 2022 |
Exhibit 10.43 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, |
|
| February 28, 2022 |
Exhibit 10.44 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. GRANT AGREEMENT Investment ID INV-016898 AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Vir Biotechnology Inc Tax Status: Not exempt from federal income tax |
|
| February 28, 2022 |
Exhibit 10.46 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (?Agreement?) is entered into as of January 12, 2022 (the ?Execution Date?), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation having an office at 500 5th Ave N, Seattle, WA 98109 (the ?Foundation?), and Vir Biotechnology, Inc. a Delaware corporation having a |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| February 24, 2022 |
Exhibit 99.2 A World Without Infectious Disease C o r p o r a t e O v e r v i e w F e b r u a r y 2 4 , 2 0 2 2 V I R B I O T E C H N O L O G Y , I N C . WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus L E G A L D I S C L A I M E R Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking stat |
|
| February 24, 2022 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results ? Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date ? ? $917.2 million of sotrovimab collaboration revenue recognized in 2021 ? ? Multiple commercial and clinical value drivers expected across the portfolio in |
|
| February 14, 2022 |
VIR / Vir Biotechnology Inc / SCANGOS GEORGE A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) VIR BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N 102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
VIR / Vir Biotechnology Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Vir Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 10, 2022 |
VIR / Vir Biotechnology Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIR BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) December 31, 2021 92764N 102 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 10, 2022 |
VIR / Vir Biotechnology Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Vir Biotechnology Inc. Title of Class of Securities: Common Stock CUSIP Number: 92764N102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone N |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2021 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 4, 2021 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir B |
|
| November 4, 2021 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results ? To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide ? ? In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized ? ? Anticipated fourth quarter milestones include: topline sotrovimab intramuscu |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| August 5, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Definitive COLLABORATION AGREEMENT By and Between Glaxo Wellcome UK Limited; And Vir Biotechnology, Inc. Table of Contents Page ARTICLE 1 DEFINITIONS 2 ARTICLE 2 EFFECTIVE |
|
| August 5, 2021 |
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results SAN FRANCISCO, August 5, 2021 ? Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. ?Vir made strong progress this quarter across our extensive infectious disease portfolio, the most notable of whic |
|
| August 5, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective January 26, 2018, as amend |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2021 Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| August 5, 2021 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone N |
|
| June 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 28, 2021 |
Vir Biotechnology, Inc. EASL ILC 2021 Hepatitis B Data Call A WORLD WITHOUT INFECTIOUS DISEASE June 25, 2021 Exhibit 99.1 Legal Disclaimers ? 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected |
|
| May 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 27, 2021 |
Exhibit 99.1 GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients ? Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COME |
|
| May 27, 2021 |
Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE May 26, 2021 Exhibit 99.2 Legal disclaimers ? 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and timing of our rese |
|
| May 24, 2021 |
Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 21, 2021 |
EX-99.1 2 d139658dex991.htm EX-99.1 Exhibit 99.1 CORRECTION — EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19 – Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive sc |
|
| May 6, 2021 |
EX-10.4 5 vir-ex104305.htm EX-10.4 Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENT This Amendment No. 1 to the Patent License Agreement (this “Amendment”) is entered into |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| May 6, 2021 |
EX-10.1 2 vir-ex101302.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Preliminary Collaboration Agreement This Preliminary Collaboration Agreement (this “Preliminary Collaboration Agreement” or “PCA”) is en |
|
| May 6, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENT This Amendment No. 1 to the Patent License Agreement (this ?Amendment?) is entered into as of the 23rd day of February, 202 |
|
| May 6, 2021 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT No. 3 TO EXCLUSIVE LICENSE AGREEMENT ThisAMENDMENTNo.3TOEXCLUSIVELICENSEAGREEMENT(this ?Amendment 3?), entered into as of March 1, 2021 (the ?Amendment 3 Date?), |
|
| May 6, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (?Agreement?) is entered into as of February 14, 2021 (the ?Execution Date?), by and between Glaxo Group Limited, a |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2021 |
Exhibit 10.6 May 4, 2021 Ann (Aine) M. Hanly VIA EMAIL Dear Aine, This letter agreement (the ?Agreement?) sets forth the terms and conditions of your continued employment with Vir Biotechnology, Inc. (?VirBio? or the ?Company?). This Agreement supersedes and replaces all prior written employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not lim |
|
| May 6, 2021 |
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results EX-99.1 2 vir-ex9916.htm EX-99.1 Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results SAN FRANCISCO, May 6, 2021 – Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. “We’ve had an active start to the year, achieving significant clinical and collaborat |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone N |
|
| April 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| April 13, 2021 |
Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE 20th Annual Needham Healthcare Conference April 13, 2021 Exhibit 99.1 Legal disclaimers ? 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the ex |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 6, 2021 |
DEF 14A 1 d318415ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
EX-10.29 5 vir-ex1029829.htm EX-10.29 Exhibit 10.29 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment Number One to License Agreement This Amendment Number One (“Amendment No. 1”) to the License Agreement dated September 7, 2018 (the “Agreement”), |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology |
|
| February 25, 2021 |
Exhibit 10.5 Vir Biotechnology, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice Vir Biotechnology, Inc. (the ?Company?), pursuant to its 2019 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to all of |
|
| February 25, 2021 |
Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. December 23, 2020 George Scangos, Ph.D. CEO & Director Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco, CA 94158 RE: Collaboration and License Agreement by and among Vir B |
|
| February 25, 2021 |
EX-10.39 7 vir-ex1039491.htm EX-10.39 Exhibit 10.39 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective January 2 |
|
| February 25, 2021 |
EX-10.38 6 vir-ex1038490.htm EX-10.38 Exhibit 10.38 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc, effective January 26 |
|
| February 25, 2021 |
EX-10.51 8 vir-ex1051886.htm EX-10.51 Exhibit 10.51 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment 2”), entered into as of September 28 |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| February 25, 2021 |
Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results SAN FRANCISCO, February 25, 2021 ? Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. ?Vir closed 2020 delivering strong progress across our entire development pipel |
|
| February 25, 2021 |
Non-Employee Director Compensation Policy. EX-10.8 3 vir-ex108229.htm EX-10.8 Exhibit 10.8 VIR BIOTECHNOLOGY, INC. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direct |
|
| February 25, 2021 |
Sublease Agreement between the Company and Dropbox, Inc., dated November 4, 2020. Exhibit 10.61 SUBLEASE BETWEEN DROPBOX, INC. AND VIR BIOTECHNOLOGY, INC. 1800 Owens Street, San Francisco, California North Tower 8th, 9th, 10th, 11th and 12th Floors SUBLEASE THIS SUBLEASE (?Sublease?) is entered into as of November 4, 2020 (the ?Effective Date?), by and between DROPBOX, INC., a Delaware corporation (?Sublandlord?), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (?Subtenant? |
|
| February 19, 2021 |
EX-99.1 Exhibit 99.1 GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses February 17, 2021 – Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza – – Functional genomics collaboration expanded to include |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vir Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vir Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) VIR BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92764N 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 11, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of S |
|
| January 28, 2021 |
EX-99.1 2 d54514dex991.htm EX-99.1 Exhibit 99.1 Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen January 26, 2021 – Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduction from baseline of 1.3 log10 IU/mL by day eight – SAN |
|
| January 28, 2021 |
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded EX-99.2 3 d54514dex992.htm EX-99.2 Exhibit 99.2 Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 January 27, 2021 INDIANAPOLIS, SAN FRANCISCO and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) — Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc ( |
|
| January 28, 2021 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 26, 2021 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commis |
|
| January 6, 2021 |
Entry into a Material Definitive Agreement - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Comm |
|
| December 29, 2020 |
Entry into a Material Definitive Agreement - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Comm |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.11 VIR BIOTECHNOLOGY, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VIR BIOTECHNOLOGY, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between Vir Biotechnology, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and e |
|
| November 10, 2020 |
As filed with the Securities and Exchange Commission on November 10, 2020 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2020 Registration No. |
|
| November 10, 2020 |
Exhibit 10.3 August 21, 2019 Steven Rice Dear Steven, This letter agreement (the ?Agreement?) sets forth the terms and conditions of your employment with Vir Biotechnology, Inc. (?VirBio? or the ?Company?). 1.Position, Location: You will serve as the Company?s Head of Human Resources and will be responsible for all duties associated with that role, along with any other duties that are assigned to |
|
| November 10, 2020 |
Exhibit 1.2 Execution Version VIR BIOTECHNOLOGY, INC. $300,000,000 COMMON STOCK SALES AGREEMENT November 10, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Vir Biotechnology, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company |
|
| November 10, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.9 VIR BIOTECHNOLOGY, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VIR BIOTECHNOLOGY, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between Vir Biotechnology, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing un |
|
| November 10, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissi |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| November 10, 2020 |
EXHIBIT 4.6 VIR BIOTECHNOLOGY, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sec |
|
| November 10, 2020 |
Exhibit 10.4 July 30, 2020 Dear Steven, I?m pleased to announce your promotion to Chief Administrative Officer. As a result of the promotion, your base salary will increase by $30,000.00, bringing your new base salary to $460,000.00 effective August 1st and will be reflected in your August 14th paycheck. Your annual target incentive will remain at 40% of your base salary. In recognition of this pr |
|
| November 10, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.10 VIR BIOTECHNOLOGY, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VIR BIOTECHNOLOGY, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between Vir Biotechnology, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and e |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2020 |
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results SAN FRANCISCO, November 10, 2020 (GLOBE NEWSWIRE) - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the third quarter ended September |
|
| September 16, 2020 |
EX-99.1 2 d94697dex991.htm EX-99.1 Exhibit 99.1 A W O R L D W I T H O U T I N F E C T I O U S D I S E A S E Vir Biotechnology, Inc. H.C. Wainwright 22nd Annual Global Investment Conference September 16, 2020 Legal disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, |
|
| September 16, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Com |
|
| September 1, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commis |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2020 |
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results SAN FRANCISCO, August 11, 2020 – Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020. “Our organiz |
|
| August 11, 2020 |
EX-10.12 2 vir-ex1012223.htm EX-10.12 Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc effective March |
|
| August 7, 2020 |
ASSIGNMENT AND NOVATION AGREEMENT EX-99.2 3 d941033dex992.htm EX-99.2 Exhibit 99.2 EXECUTION COPY – 31 July 2020 ASSIGNMENT AND NOVATION AGREEMENT THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Assignment Agreement”) is made as of July 31, 2020 (“Assignment Date”), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 U.S.A (“Assi |
|
| August 7, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39083 81-2730369 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2020 |
ASSIGNMENT AND NOVATION AGREEMENT EX-99.1 Exhibit 99.1 Confidential Execution Copy 29 July 2020 ASSIGNMENT AND NOVATION AGREEMENT THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Agreement”) is made as of July 29, 2020 (“Assignment Date”), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 U.S.A (“Assignor”), GlaxoSmithKline Trad |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vir Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92764N 102 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone Numbe |
|
| July 8, 2020 |
POS EX As filed with the Securities and Exchange Commission on July 7, 2020. Registration No. 333-239689 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-2730369 (State or other juri |
|
| July 8, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-239689 Registration No. 333-239747 PROSPECTUS 7,142,857 Shares Common Stock We are offering 7,142,857 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the trading symbol “VIR.” The last reported sale price of our common stock on The Nasdaq Global Select Market on July 7, 202 |
